Both the 2RT inventor and the 2RT lead researcher have featured on the very prestigious ophthalmology Power List this year which is incredibly exciting and is further evidence of the quality of the people involved in this revolutionary new technology, as well as industry recognition of the importance of 2RT. Interesting to also note comments by many of the other Power List names in relation to the importance of earlier intervention, an area in which Nova Eye Medical is leading. The phrase "interventional glaucoma management" (earlier intervention via MIGS as opposed to decades of drops) was specifically mentioned many times by many different leading doctors and researchers as one of the biggest trends in ophthalmology, which is incredibly bullish for iTrack Advance of course. iTrack Advance is arguably one of the best options for earlier intervention, given the fact it is the only device that does not leave a stent behind or cause tearing, making it much "easier to swallow" compared to alternative options. Not to mention the high efficacy, safety, efficiency and ease of use!
Glaucoma:
The Power List
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
-0.003(1.64%) |
Mkt cap ! $34.35M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.5¢ | 15.0¢ | $55.25K | 367.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 265089 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 38431 | 2 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| EYE (ASX) Chart |